ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Research ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (R9Z) on Bullrun: market cap EUR 166.27M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerR9Z
• ExchangeF
• CountryChina
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 166.27M
• Financial periodFY2024
• RevenueEUR 74.15M
• Revenue growth19109.6%
• Net income-EUR 315.86M
• Free cash flow-EUR 138.44M

Valuation Snapshot

latest market cap is EUR 166.27M.

About ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in China and the United States. The company's core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma;

Frequently asked questions

What is ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s market cap?

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s market capitalization is EUR 166.27M.

What does ImmuneOnco Biopharmaceuticals (Shanghai) Inc. do?

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in China and the United States.